We determine the sizes of orbits from the action of subgroups of PSL(2,q) on projective line X = GF(q) ∪ {∞} with q a prime power and congruent to 1 modulo 4.As an example of its application,we construct some new fa...We determine the sizes of orbits from the action of subgroups of PSL(2,q) on projective line X = GF(q) ∪ {∞} with q a prime power and congruent to 1 modulo 4.As an example of its application,we construct some new families of simple 3-designs admitting PSL(2,q) as automorphism group.展开更多
近年来多巴胺D3受体(DRD_(3))在神经系统疾病的治疗过程中受到大量关注,包括帕金森、精神分裂、药物依赖等。本文综述2015年至今多巴胺D3受体选择性配体的研究进展,并以分子动力学原理为基础,利用Discovery Studio 4.5软件评价了这些配...近年来多巴胺D3受体(DRD_(3))在神经系统疾病的治疗过程中受到大量关注,包括帕金森、精神分裂、药物依赖等。本文综述2015年至今多巴胺D3受体选择性配体的研究进展,并以分子动力学原理为基础,利用Discovery Studio 4.5软件评价了这些配体的选择性,建立了基于分子共同特征的药效团模型,从类药分子库中筛选出对设计新型配体具有先导化合物意义的小分子化合物,以期对D3受体选择性配体的研究提供参考。展开更多
基金supported by National Natural Science Foundation of China (Grant Nos.10871205 and 10971252)the Research Foundation of Education Bureau of Hunan Province of China (Grant No. 08c021)
文摘We determine the sizes of orbits from the action of subgroups of PSL(2,q) on projective line X = GF(q) ∪ {∞} with q a prime power and congruent to 1 modulo 4.As an example of its application,we construct some new families of simple 3-designs admitting PSL(2,q) as automorphism group.
文摘近年来多巴胺D3受体(DRD_(3))在神经系统疾病的治疗过程中受到大量关注,包括帕金森、精神分裂、药物依赖等。本文综述2015年至今多巴胺D3受体选择性配体的研究进展,并以分子动力学原理为基础,利用Discovery Studio 4.5软件评价了这些配体的选择性,建立了基于分子共同特征的药效团模型,从类药分子库中筛选出对设计新型配体具有先导化合物意义的小分子化合物,以期对D3受体选择性配体的研究提供参考。
